Dosing & Uses
Dosing Strengths & Forms
powder for injection
Indicated for moderate-to-severe chronic plaque psoriasis
15 mg IM qWeek x 12 weeks
Regimen of 12 weekly injections recommended
Retreatment with additional 12 week course may be initiated, based on normal CD4+ T lymphocyte counts and a minimum 12 week interval
Serious - Use Alternative
Significant - Monitor Closely
Injection site reactions (16%)
ALT/AST elevation (1.7%)
CD4+ T lymphocyte count below normal
Pts at high risk for malignancy
Monitor CD4+ T lymph counts weekly; withhold dosing if CD4 <250/mcL; discontinue if CD4 <250/mcL for one month
Pts who become pregnant should enroll in the Biogen Pregnancy Registry (1-866-263-8483)
May increase risk of malignancies
Risk of serious infection, anaphylaxis
15 mg lyophilized powder for IM administration ; 7.5 mg lyophilized powder for IV administration
Pregnancy & Lactation
Pregnancy Category: B
Lactation: excretion in milk unknown/not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Recombinant dimeric fusion protein: extracellular CD2-binding portion of human leukocyte function antigen-3 (LFA-3) linked to the Fc portion of human IgG1
Inhibits LFA-3/CD2 interaction, thus inhibits T lymphocyte activation (decreases CD45RO+ T lymphs)
Bioavailability: 63% (IM)
Vd: 94 mL/kg (IV)
Half-Life: 270 hr (IV)
Clearance: 0.25 mL/kg/hr (IV)
IV: reconsitute 7.5 mg vial with 0.6 mL of the supplied diluent; 0.5 mL will contain 7.5 mg of drug
IM: reconstitute 15 mg vial with 0.6 mL of supplied diluent; 0.5 mL will contains 15 mg of drug
Withdraw 0.6 mL of supplied diluent using supplied syringe & needle
Keep needle pointed at sidewall of vial & slowly inject diluent
Gently swirl contents during dissolution; do not shake
Reconstituted solution should be clear & colorless to slightly yellow; inspect solution for particulate matter
Do not use if discolored, cloudy, or if undissolved material remains
Do not reconstitute drug with other diluents
Do not filter reconstituted solution during preparation or administration
Use immediately or within 4 hr if stored in the vial at 2-8°C (36-46°F)
Do not add other medications to solutions containing drug
- Withdraw & inject the full 0.5 mL of solution
- Rotate injection sites
- Give new injections at least 1 inch from an old site & never into areas where skin is tender, bruised, red, or hard
- Prepare 2 syringes with 3 mL NS for pre- & post-administration flush
- Prime the winged infusion set with 3 mL NS & insert into vein
- Attach drug-filled syringe to infusion set & administer over no more than 5 sec
- Flush infusion set with 3 mL NS
Storage Store between 2-8°C/36-46°F Protect from light
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.